Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Genesis Reports Higher Revenues, Flat Net

publication date: Feb 17, 2009

Genesis Pharmaceuticals Enterprises, Inc. (江波制药) reported that revenues jumped 24% during its Q2 (ended December 31, 2008), but net income moved up only 4%. The company booked $32.9 in revenue for the quarter and recorded a profit of $5.4 million or 11 cents per share. At current levels, Genesis has a market capitalization of less than its cash level.  More details...

Stock Symbol: (OTCBB: GNPH)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital